Analystreport

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $135.00 price target on the stock.

Ligand Pharmaceuticals Incorporated  (LGND) 
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.ligand.com